Cupid Limited Achieves Strong Q1 FY27 Results; Ups FY27 Guidance to ₹ 750 Cr Revenue and ₹ 225 Cr Net Profit

Cupid Limited Achieves Strong Q1 FY27 Results; Ups FY27 Guidance to ₹ 750 Cr Revenue and ₹ 225 Cr Net Profit​

Mumbai, August 7, 2026: Consumer wellness company Cupid Limited announced robust financial results for the quarter ended June 30, 2026. The strong performance across its international B2B healthcare and domestic consumer businesses led management to enhance the full-year FY27 guidance, forecasting revenue between ₹ 725 Cr and ₹ 750 Cr and Net Profit of ₹ 210 Cr to ₹ 225 Cr.

The results were supported by continuous business momentum, expanding order visibility, and strategic initiatives across key operating segments.

Key Consolidated Financial Highlights​

Cupid reported significant growth metrics in Q1 FY27 compared to previous periods:

Business Drivers and Strategic Moves​

The Company commenced FY27 with strong momentum in its international B2B healthcare and domestic Consumer Healthcare & FMCG segments. Robust demand was observed across the company’s international B2B business, spanning PFSCM, WHO/UNFPA, institutional procurement programmes, government tenders, and private export markets, ensuring a healthy revenue pipeline.

The growth in operating income reflects the increasing contribution from core operating businesses. The Company noted that it has implemented a minimum 10% price increase across its export portfolio, contributing to improved realizations and margin expansion. Furthermore, a favourable USD/INR environment supported export realizations, aided by prudent hedging of currency risk related to international investments.

In terms of domestic operations, during FY26, the Consumer Healthcare & FMCG portfolio contributed ₹ 121.61 crore in revenue, which included domestic sales of male and female condoms, IVD kits, personal lubricants, and ₹ 84.26 crore from the newly launched FMCG products.

The company also announced strategic investments in Baazar Style Retail and GII Healthcare, intended to support long-term shareholder value creation by strengthening its healthcare ecosystem and consumer platform.

Operational Capacity and Future Outlook​

Cupid Limited is enhancing its manufacturing capacity with the Palava facility in Maharashtra, which is scheduled for commissioning during Q2 FY27. This facility is designed to support an annual capacity of approximately 1.25 billion male condoms and 125 million female condoms, offering incremental capacity additions of roughly 770 million male condoms and 75 million female condoms. The site incorporates dual-polymer dipping technology, Natural Rubber Latex and Nitrile capabilities, dedicated production lines, and interchangeable manufacturing lines to boost flexibility and operating leverage.

The revised FY27 guidance reflects management confidence in sustained growth, supported by a strong order book, healthy international B2B demand, and the expansion of the Consumer Healthcare & FMCG portfolio. The revised outlook is summarized below:


Similarly, the Net Profit estimates for FY27 have been raised from the original estimate of ₹ 180 Cr to a latest revised range of ₹ 210 Cr - ₹ 225 Cr.

Management Commentary​

Aditya Kumar Halwasiya, Chairman and Managing Director of Cupid Limited, commented on the performance, stating that strong execution and improving order visibility across core segments have fortified confidence in the Company's growth trajectory.

He noted that the international B2B healthcare business continues to demonstrate healthy momentum through diversified order pipelines from PFSCM, WHO/UNFPA, government tenders, and private export markets, reinforcing its leadership in global healthcare. Furthermore, he highlighted that the commissioning of the Palava facility during Q2 FY27 will enhance manufacturing flexibility and support future growth for both international B2B and domestic Consumer Healthcare & FMCG businesses.

CUPID Stock Price Movement​

On Friday, Cupid Limited shares edged higher, closing at ₹262.13 after gaining 0.13%. The stock traded a significant volume of 46.03 million shares while trading near its 52-week high mark.